234 related articles for article (PubMed ID: 11303049)
21. Potency and selectivity of RXP407 on human, rat, and mouse angiotensin-converting enzyme.
Vazeux G; Cotton J; Cuniasse P; Dive V
Biochem Pharmacol; 2001 Apr; 61(7):835-41. PubMed ID: 11274969
[TBL] [Abstract][Full Text] [Related]
22. Development of potent and selective phosphinic peptide inhibitors of angiotensin-converting enzyme 2.
Mores A; Matziari M; Beau F; Cuniasse P; Yiotakis A; Dive V
J Med Chem; 2008 Apr; 51(7):2216-26. PubMed ID: 18324760
[TBL] [Abstract][Full Text] [Related]
23. Effect of new peptide inhibitors on the ratio of angiotensin I-converting and kinin-degrading activities of dipeptidyl carboxypeptidase (angiotensin-converting enzyme).
Kalinina EV; Posdnev VF; Komissarova NV; Gomazkov OA
Biochemistry (Mosc); 1997 Mar; 62(3):247-50. PubMed ID: 9275297
[TBL] [Abstract][Full Text] [Related]
24. Single-domain angiotensin I converting enzyme (kininase II): characterization and properties.
Deddish PA; Wang LX; Jackman HL; Michel B; Wang J; Skidgel RA; Erdös EG
J Pharmacol Exp Ther; 1996 Dec; 279(3):1582-9. PubMed ID: 8968386
[TBL] [Abstract][Full Text] [Related]
25. The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme.
Rousseau A; Michaud A; Chauvet MT; Lenfant M; Corvol P
J Biol Chem; 1995 Feb; 270(8):3656-61. PubMed ID: 7876104
[TBL] [Abstract][Full Text] [Related]
26. Inhibitor analysis of angiotensin I-converting and kinin-degrading activities of bovine lung and testicular angiotensin-converting enzyme.
Grinshtein SV; Binevski PV; Gomazkov OA; Pozdnev VF; Nikolskaya II; Kost OA
Biochemistry (Mosc); 1999 Aug; 64(8):938-44. PubMed ID: 10498812
[TBL] [Abstract][Full Text] [Related]
27. Do studies with ACE N- and C-domain-selective inhibitors provide evidence for a non-ACE, non-chymase angiotensin II-forming pathway?
Husain A; Li M; Graham RM
Circ Res; 2003 Jul; 93(2):91-3. PubMed ID: 12881473
[No Abstract] [Full Text] [Related]
28. ACE inhibition and protection from doxorubicin-induced cardiotoxicity in the rat.
Sacco G; Mario B; Lopez G; Evangelista S; Manzini S; Maggi CA
Vascul Pharmacol; 2009; 50(5-6):166-70. PubMed ID: 19344651
[TBL] [Abstract][Full Text] [Related]
29. Domain-selective ligand-binding modes and atomic level pharmacophore refinement in angiotensin I converting enzyme (ACE) inhibitors.
Tzakos AG; Gerothanassis IP
Chembiochem; 2005 Jun; 6(6):1089-103. PubMed ID: 15883972
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic resistance to angiotensin converting enzyme (ACE) inhibition is related to pharmacodynamic and -kinetic factors in 5/6 nephrectomized rats.
Windt WA; van Dokkum RP; Kluppel CA; Jeronimus-Stratingh CM; Hut F; de Zeeuw D; Henning RH
Eur J Pharmacol; 2008 Feb; 580(1-2):231-40. PubMed ID: 18036585
[TBL] [Abstract][Full Text] [Related]
31. The influence of angiotensin converting enzyme mutations on the kinetics and dynamics of N-domain selective inhibition.
Lubbe L; Sewell BT; Sturrock ED
FEBS J; 2016 Nov; 283(21):3941-3961. PubMed ID: 27636235
[TBL] [Abstract][Full Text] [Related]
32. Angiotensin-converting enzyme-2 (ACE2): comparative modeling of the active site, specificity requirements, and chloride dependence.
Guy JL; Jackson RM; Acharya KR; Sturrock ED; Hooper NM; Turner AJ
Biochemistry; 2003 Nov; 42(45):13185-92. PubMed ID: 14609329
[TBL] [Abstract][Full Text] [Related]
33. Antihypertensive effect of rice protein hydrolysate with in vitro angiotensin I-converting enzyme inhibitory activity in spontaneously hypertensive rats.
Li GH; Qu MR; Wan JZ; You JM
Asia Pac J Clin Nutr; 2007; 16 Suppl 1():275-80. PubMed ID: 17392118
[TBL] [Abstract][Full Text] [Related]
34. Structure of angiotensin I-converting enzyme.
Sturrock ED; Natesh R; van Rooyen JM; Acharya KR
Cell Mol Life Sci; 2004 Nov; 61(21):2677-86. PubMed ID: 15549168
[TBL] [Abstract][Full Text] [Related]
35. Catabolism of the hemoregulatory peptide N-Acetyl-Ser-Asp-Lys-Pro: a new insight into the physiological role of the angiotensin-I-converting enzyme N-active site.
Rousseau-Plasse A; Lenfant M; Potier P
Bioorg Med Chem; 1996 Jul; 4(7):1113-9. PubMed ID: 8831983
[TBL] [Abstract][Full Text] [Related]
36. Pharmacodynamic effects of C-domain-specific ACE inhibitors on the renin-angiotensin system in myocardial infarcted rats.
Sharp S; Poglitsch M; Zilla P; Davies NH; Sturrock ED
J Renin Angiotensin Aldosterone Syst; 2015 Dec; 16(4):1149-58. PubMed ID: 25757657
[TBL] [Abstract][Full Text] [Related]
37. Myelopoiesis modulation by ACE hyperfunction in kinin B(1) receptor knockout mice: relationship with AcSDKP levels.
Oliveira CR; Paredes-Gamero EJ; Barbosa CM; Nascimento FD; Batista EC; Reis FC; Martins AH; Ferreira AT; Carmona AK; Pesquero JB; Tersariol IL; Araújo RC; Bincoletto C
Chem Biol Interact; 2010 Mar; 184(3):388-95. PubMed ID: 20096676
[TBL] [Abstract][Full Text] [Related]
38. Apparent kinetics of angiotensin converting enzyme: hydrolysis of [3H]benzoyl-phenylalanyl-alanyl-proline in the isolated perfused lung.
Ashton JH; Pitt BR; Gillis CN
J Pharmacol Exp Ther; 1985 Mar; 232(3):602-7. PubMed ID: 2983065
[TBL] [Abstract][Full Text] [Related]
39. Procyanidin structure defines the extent and specificity of angiotensin I converting enzyme inhibition.
Ottaviani JI; Actis-Goretta L; Villordo JJ; Fraga CG
Biochimie; 2006; 88(3-4):359-65. PubMed ID: 16330143
[TBL] [Abstract][Full Text] [Related]
40. New ketomethylene inhibitor analogues: synthesis and assessment of structural determinants for N-domain selective inhibition of angiotensin-converting enzyme.
Sharma RK; Douglas RG; Louw S; Chibale K; Sturrock ED
Biol Chem; 2012 May; 393(6):485-93. PubMed ID: 22628311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
